Kancera AB Financials
| KAN Stock | SEK 1.10 0.04 3.77% |
Kancera |
Understanding current and past Kancera AB Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kancera AB's financial statements are interrelated, with each one affecting the others. For example, an increase in Kancera AB's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Kancera AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kancera AB. Check Kancera AB's Beneish M Score to see the likelihood of Kancera AB's management manipulating its earnings.
Kancera AB Stock Summary
Kancera AB competes with Combigene, Cantargia, Spectrumone Publ, and BioInvent International. Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.| Foreign Associate | Germany |
| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0015658570 |
| Business Address | Karolinska Institutet Science |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.kancera.com |
| Phone | 46 8 50 12 60 80 |
| Currency | SEK - Swedish Kronor |
You should never invest in Kancera AB without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Kancera Stock, because this is throwing your money away. Analyzing the key information contained in Kancera AB's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Kancera AB Key Financial Ratios
Kancera AB's financial ratios allow both analysts and investors to convert raw data from Kancera AB's financial statements into concise, actionable information that can be used to evaluate the performance of Kancera AB over time and compare it to other companies across industries.| Return On Equity | -0.47 | |||
| Return On Asset | -0.27 | |||
| Target Price | 1.6 | |||
| Beta | 1.28 |
Kancera Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kancera AB's current stock value. Our valuation model uses many indicators to compare Kancera AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kancera AB competition to find correlations between indicators driving Kancera AB's intrinsic value. More Info.Kancera AB is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kancera AB's earnings, one of the primary drivers of an investment's value.Kancera AB Systematic Risk
Kancera AB's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kancera AB volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Kancera AB correlated with the market. If Beta is less than 0 Kancera AB generally moves in the opposite direction as compared to the market. If Kancera AB Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kancera AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kancera AB is generally in the same direction as the market. If Beta > 1 Kancera AB moves generally in the same direction as, but more than the movement of the benchmark.
Kancera AB November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kancera AB help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kancera AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kancera AB based on widely used predictive technical indicators. In general, we focus on analyzing Kancera Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kancera AB's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 48.95 | |||
| Value At Risk | (11.59) | |||
| Potential Upside | 6.7 |
Additional Tools for Kancera Stock Analysis
When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.